Login / Signup

Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.

Lianna J MarksQinglin PeiRizvan BushAllen BuxtonBurton AppelKara M KellyCindy L SchwartzDebra L Friedman
Published in: Pediatric blood & cancer (2018)
Children and adolescents with intermediate-risk LPHL represent ideal candidates for response-adapted therapy based on their favorable outcomes. The majority of patients treated with the ABVE-PC backbone achieve RER with CR status and can be treated successfully without IFRT.
Keyphrases
  • hodgkin lymphoma
  • young adults
  • palliative care
  • stem cells
  • type diabetes
  • adipose tissue
  • peripheral blood
  • mesenchymal stem cells
  • bone marrow
  • cell therapy